pulmicort and Oral-Ulcer

Oral chronic graft versus host disease (cGVHD) is often refractory to systemic therapies. Additional topical treatment is commonly required. The potency of the agent, the vehicle and formulation in which it is delivered are all critical factors in determining the effectiveness of topical therapies. High potency of budesonide, combined with its very low bioavailability when absorbed through mucosal surfaces, increased the potential role in topical application for oral cGVHD. Viscous formulation increases mucosal contact time resulting in a greater decrease in mucosal inflammation. This short communication suggests that oral viscous budesonide should be considered as a potential new therapy in the management of oral cGVHD.

Topics: Administration, Topical; Budesonide; Child; Chronic Disease; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Mouth Diseases; Mouth Mucosa; Oral Ulcer

A chronic ulcer of the tongue is reported, resulting from the use of inhalers for respiratory disease. This complication was managed by the use of a spacer device.

Topics: Administration, Inhalation; Aged; Aged, 80 and over; Albuterol; Bronchodilator Agents; Budesonide; Equipment and Supplies; Female; Humans; Nebulizers and Vaporizers; Oral Ulcer; Pregnenediones; Product Surveillance, Postmarketing; Tongue; Tongue Diseases; United Kingdom